Navigation Links
Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
Date:11/2/2010

he excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment.  Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients.  The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

About Cadence Pharmaceuticals

Cadence Pharmaceuticals is a biopharmaceutical company committed to in-licensing, developing and commercializing proprietary product candidates to improve the lives of hospitalized patients. For more information about Cadence, please visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the timing of the planned commercial launch of OFIRMEV, the market potential for OFIRMEV, OFIRMEV's ability to fulfill unmet medical needs in the treatment of pain and fever in the hospital setting, and the timing of a post-marketing efficacy study of OFIRMEV in infants and neonates.  Actual results may differ materially from those set forth in this press release and the conference call due to the risks and uncertainties inherent in the company's business, in
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
10. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... , SAN DIEGO, July 27 Neurocrine Biosciences (Nasdaq: NBIX ) ... Neurocrine Biosciences Webcast, When: July 30, 2009 ... Live over the Internet -- Simply log on to the web ... above., Contact: Jane Sorenson of Neurocrine Biosciences, +1-858-617-7653., , ...
... , , , ... (PTC) today announced the initiation of a Phase 2 clinical ... (NF2), a rare genetic disorder that causes the development of ... investigational new drug that is designed to selectively block tumor-related ...
... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced ... SAFC Pharma(R), a Division of Sigma-Aldrich Corporation, it has ... under cGMP conditions. This run is anticipated to be ... the next several years as Oncolytics provides product for ...
Cached Biology Technology:PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R) 2
(Date:7/9/2014)... are turning to more healthful alternatives to their savored ... mean low satisfaction. Now researchers are reporting new progress ... are made with olive oil rather than pork fat. ... Agricultural and Food Chemistry . , Ana M. Herrero ... expect just the right amount of chewiness and springiness, ...
(Date:7/9/2014)... on the verge of an economy driven by methane, the ... and is undergoing a production boom. It has poised the ... is casting serious doubts over just how climate-friendly it is, ... (C&EN), the weekly news magazine of the American Chemical ... at C&EN, explains that when burned as a fuel to ...
(Date:7/9/2014)... protect neuronal function and increase the survival rate ... her team, School of Pharmaceutical Sciences, Southwest University, ... mice were administered with low dose of levothyroxine ... aged rats exhibited an obvious improvement in cognitive ... to 93%. The underlying mechanism was demonstrated that ...
Breaking Biology News(10 mins):
... The first State of the Carbon Cycle Report for North ... Science Program, finds the continents carbon budget increasingly overwhelmed by ... tons of carbon into the atmosphere each year, mostly as ... may remove up to half this amount, but these current ...
... In the December 1st issue of G&D, Dr. Hailing ... of a new class of small RNAs in Arabidopsis. ... dubbed long short interfering RNAs (lsiRNAs), and are induced ... liRNAs share some hallmark features with other, previously identified ...
... Researchers from Kaiser Permanente and the California Department of ... nationwide, today will begin enrolling families in the largest ... that may cause autism and other developmental disabilities. ... Early Development, will involve 2,700 children and their parents ...
Cached Biology News:First-ever 'State of the Carbon Cycle Report' finds troubling imbalance 2Largest study to investigate risk factors of autism to begin enrolling families 2
... Unique, compact measuring instrument for calibrating single-channel ... design and the robust carrying case, the ... in the laboratory and on-site at the ... to use because the individual channels are ...
... DTT White solid.. PACKAGED UNDER INERT ... so reaction is "driven" to completion. A protective ... surfactant found in many other preparations. Blocks the ... ≥97% by titration. Contaminants: Heavy metals: ...
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. cerevisiae) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
... Basically, most ``special`` dye stains ... a few other non-routine) stains are ... of a paraffin block, staining, coverslipping ... Stain (for senile plaques) ,Bodian`s Stain ...
Biology Products: